This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Cigna (CI) Beat Q2 Earnings on Growing Pharmacy Revenues?
by Zacks Equity Research
Cigna's (CI) second-quarter earnings are expected to benefit from rising premiums and pharmacy revenues, partially offset by rising expenses.
Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Corcept (CORT) beats on both earnings and sales in the second quarter of 2024. The company increases revenue guidance for 2024.
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Sustained Product Demand Likely to Aid BD's (BDX) Q3 Earnings
by Zacks Equity Research
Continued solid uptake of BD's (BDX) products is expected to have driven fiscal third-quarter revenues.
Implied Volatility Surging for United Therapeutics (UTHR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to United Therapeutics (UTHR) stock based on the movements in the options market lately.
Will PTC Therapeutics (PTCT) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
If You Invested $1000 in United Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
UTHR vs. CTLT: Which Stock Is the Better Value Option?
by Zacks Equity Research
UTHR vs. CTLT: Which Stock Is the Better Value Option?
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
UTHR vs. CTLT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
UTHR vs. CTLT: Which Stock Is the Better Value Option?
5 High ROE Stocks to Buy as Low Inflation Fuels Rate Cut Hopes
by Supriyo Bose
United Therapeutics (UTHR), ABB (ABBNY), Lockheed Martin (LMT), MPLX (MPLX) and Banco de Chile (BCH) are some of the stocks with high ROE to profit from as easing inflationary pressures ignite rate cut hopes.
Is United Therapeutics (UTHR) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
United Therapeutics (UTHR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
What Makes United Therapeutics (UTHR) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does United Therapeutics (UTHR) have what it takes to be a top stock pick for momentum investors? Let's find out.
UTHR or CTLT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
UTHR vs. CTLT: Which Stock Is the Better Value Option?
United Therapeutics Corporation (UTHR) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
United Therapeutics (UTHR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
United Therapeutics (UTHR) Completes Enrolment in IPF Study
by Zacks Equity Research
United Therapeutics' (UTHR) late-stage study is evaluating Tyvaso inhalation solution in IPF patients living outside the United States and Canada.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
by Zacks Equity Research
Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.